Core Viewpoint - Huayang Intelligent's large-dose high-viscosity continuous injection device is currently in the functional prototype verification stage, and the company is collaborating with clients on foundational drug delivery research. The commercialization of this product is closely tied to the drug approval process, and since the related drug is still in the early research phase, it will not impact the company's revenue in the short term [1] Group 1 - The large-dose high-viscosity continuous injection device is in the functional prototype verification stage [1] - The company is working with clients on foundational drug delivery research [1] - The commercialization of the product is linked to the drug approval process [1] Group 2 - The related drug is still in the early research phase [1] - The product will not have a short-term impact on the company's revenue [1]

Financial Performance - Revenue in the first three quarters decreased by 14.52%, but net profit attributable to shareholders in Q3 increased by 61.24%, and non-recurring net profit surged by 107.84%. The improvement in profitability is attributed to effective cost and expense management despite declining revenue [1] - Financial expenses increased by 224.45% year-on-year, while sales and management expenses decreased by 35.33% and 21.40%, respectively. The rise in financial expenses is mainly due to interest from structured deposits, while the decrease in sales and management expenses is due to reduced advertising costs and lower operational expenses [2] Core Business Operations - The micro-special motor and components business accounted for 92.63% of revenue in the first half of the year. However, sales volume and prices have shown a temporary decline due to structural pressure in downstream markets such as home appliances and medical devices [2] - The precision injection drug delivery device business represented 6.36% of revenue in the first half. The development of high-viscosity continuous injection devices is ongoing, currently in the functional prototype verification stage, with commercialization closely tied to the drug approval process [2] - Accounts receivable increased by 24.06% year-on-year, significantly outpacing revenue decline. The increase is attributed to delayed pricing cycles and outstanding payments from clients. The company has implemented measures to enhance credit management and payment assessment mechanisms [3] Research and Development - The focus for 2025 is on the core technology of frameless motors, with ongoing development and market application assessments. Product mass production has not yet been achieved [3] - R&D expenses decreased by 15.43% year-on-year, primarily due to management optimization and efficiency improvements. This reduction will not impact the progress of key projects such as frameless motors and high-viscosity injection devices [3]